LYMPHOCYTE ACTIVATION GENE-3 PROTEIN MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026 - 2033)

Lymphocyte Activation Gene-3 Protein Market Size Analysis- 2026 To 2033

The Lymphocyte Activation Gene-3 (LAG-3) Protein Market size is anticipated to grow at a CAGR of 9.1%, with a market value of USD 1.64 Bn in 2026, and is expected to reach USD 3.01 Bn by 2033. The primary growth drivers are largely defined by the increasing adoption of LAG-3-targeted immunotherapies, rising prevalence of cancer, growing use of immune checkpoint inhibitors, and expanding clinical development of LAG-3 antibodies and fusion-protein candidates. According to Bristol Myers Squibb reports that worldwide sales of Opdualag (nivolumab and relatlimab-rmbw) reached approximately USD 1.185 Bn in 2025, demonstrating the increasing commercial significance of LAG-3-directed cancer immunotherapy.

Key Takeaways

• The BMS-986016 (relatlimab) segment is expected to hold the largest market share of 72.5% in 2026. The segment is predicted to dominate the segment with the commercial availability of relatlimab via Opdualag (nivolumab and relatlimab-rmbw) and its status as the first FDA-approved LAG-3-blocking therapy. Bristol Myers Squibb reported Opdualag sales of USD 644 million in the first half of 2026 versus USD 537 million in the first half of 2025, up about 19.9% year-over-year.
• The melanoma segment is projected to lead the market with an estimated 61.0% share in 2026. The segment’s prominence is supported by the established use of LAG-3 inhibition in unresectable or metastatic melanoma and the commercial maturity of Opdualag in this indication compared with other LAG-3 applications that remain under clinical development. In the U.S., the American Cancer Society estimates approximately 112,000 new melanoma cases in 2026, including 65,400 cases in men and 46,600 cases in women.
• North America is expected to account for the prominent regional share of approximately 43.0% in 2026. The region’s standing is bolstered by early regulatory adoption of LAG-3 checkpoint inhibition, high levels of oncology R&D activity, established use of immune checkpoint inhibitors and the strong commercial presence of Bristol Myers Squibb in the U.S. According to the FDA advisory-committee briefing document, July 2026, a substantial number of U.S. patients with melanoma are now treated with nivolumab plus ipilimumab or relatlimab plus nivolumab (Opdualag) as first-line therapy, indicating that anti-LAG-3 therapy has become an established treatment option in the U.S. melanoma treatment pathway.

Market Drivers

Growing Adoption of Dual Checkpoint Inhibition is Driving the Lymphocyte Activation Gene-3 Protein Market

The Lymphocyte Activation Gene-3 Protein Market is gaining momentum due to the increasing use of LAG-3 in combination with established immune-checkpoint pathways such as PD-1. LAG-3 inhibition provides an additional mechanism for restoring T-cell activity in tumors, supporting its integration into combination immunotherapy strategies across melanoma and other solid tumors.

In a July 2026 briefing document, the FDA noted that many U.S. patients with melanoma are now being treated in the first-line setting with either nivolumab plus ipilimumab or relatlimab plus nivolumab (Opdualag). The document also noted broader clinical integration of LAG-3-based combinations as the use of relatlimab with nivolumab expanded more broadly into the neoadjuvant treatment setting.

Expansion of LAG-3 Therapies Across Multiple Cancer Indications is Supporting Market Growth

The market is also being propelled by ongoing clinical exploration of LAG-3-targeting agents outside of melanoma, including non-small cell lung cancer, head and neck cancer, metastatic breast cancer, and soft tissue sarcoma. This expanding clinical scope opens opportunities for LAG-3 proteins to become components of treatment regimens across several high-burden malignancies.

Further regulatory support was seen in April 2026 when the U.S. FDA granted Orphan Drug Designation to eftilagimod alfa for soft tissue sarcoma. The designation is for diseases affecting fewer than 200,000 people in the U.S. and provides development incentives that may further support the continued advancement of LAG-3-based therapies into additional oncology indications.

Current Events and Their Impact on the Lymphocyte Activation Gene-3 Protein Market

Segmental Insights

Why is BMS-986016 (Relatlimab) Acquiring the Largest Share?

On the basis of drug, the BMS-986016 (relatlimab) segment is expected to account for the largest Lymphocyte Activation Gene-3 Protein Market share of approximately 72.5% in 2026. The segment’s dominance is owing to relatlimab’s established clinical position as a LAG-3-blocking antibody, its use alongside nivolumab in dual immune-checkpoint inhibition, and substantially greater commercial maturity compared with most competing LAG-3 candidates that remain under clinical development.

Recent 2026 five-year follow-up data from the Phase II/III RELATIVITY-047 study continued to demonstrate durable clinical benefit for nivolumab plus relatlimab. With a minimum follow-up of 57.3 months, the combination recorded a progression-free survival hazard ratio of 0.77 versus nivolumab alone and an overall-survival hazard ratio of 0.78. The analysis used a November 2025 database lock and included a median potential follow-up of approximately 80 months, providing long-term evidence supporting relatlimab-based therapy.

Why is Melanoma Acquiring the Largest Share?

On the basis of cancer type, the melanoma segment is projected to account for the largest Lymphocyte Activation Gene-3 Protein Market share of approximately 61.0% in 2026. The segment’s dominance is owing to the comparatively advanced adoption of LAG-3 inhibition in melanoma, the established role of dual LAG-3/PD-1 checkpoint blockade in first-line treatment, and continued investigation of LAG-3-containing regimens across neoadjuvant, adjuvant, and advanced-disease settings.

In July 2026 FDA advisory-committee presentation showed that relatlimab plus nivolumab has become sufficiently established in melanoma that it was selected as the control-arm treatment in more than 95% of cases for the planned IGNYTE-3 comparator setting. The same FDA material also notes that the combination is included in NCCN 2026 melanoma guidelines for second-line use, with reported objective response rates of approximately 9%–12% in that setting.

In May 2026, Regeneron Pharmaceuticals announced Phase III results for fianlimab, its LAG-3 inhibitor, in combination with cemiplimab for first-line unresectable or metastatic melanoma. The high-dose combination achieved a median progression-free survival of 11.5 months versus 6.4 months with pembrolizumab.

Lymphocyte Activation Gene-3 Protein Market Trends

• The increasing use of dual-checkpoint inhibition involving LAG-3 and PD-1 is reshaping the competitive landscape of the market. Companies are shifting from single-target checkpoint therapy to combination regimens to enhance antitumor immune activation. In May 2026, Regeneron shared Phase III data for LAG-3 inhibitor fianlimab in combination with cemiplimab and affirmed that a separate Phase III head-to-head study versus Opdualag (nivolumab + relatlimab) is in progress, underscoring continued competition in the LAG-3 class.
• The market is moving toward next-generation LAG-3 modalities beyond traditional blocking antibodies including soluble LAG-3 proteins, agonist antibodies and bispecific constructs. In July 2026, Immutep announced that IMP761 is the only LAG-3 agonist antibody currently in clinical development and demonstrated encouraging first-in-human pharmacodynamic activity, representing an expansion of LAG-3 targeting into autoimmune and inflammatory disease applications.
• The market is increasingly moving toward indication diversification beyond melanoma. LAG-3-targeting programs are being evaluated across lung cancer, breast cancer, head and neck cancer, soft tissue sarcoma, and other solid tumors. Immutep’s 2026 pooled analysis covered 592 patients across five trials and four tumor types, while biological responders to eftilagimod alfa-based treatment demonstrated a 7.7-month improvement in median overall survival, supporting continued investigation of LAG-3 biology across multiple cancer.

Regional Insights

North America Dominates Owing to Strong Clinical Development and Early Adoption of LAG-3 Immunotherapies

The North America region is expected to account for approximately 43.0% of the Lymphocyte Activation Gene-3 Protein Market in 2026. The region’s dominance is supported by the early clinical adoption of LAG-3-directed immunotherapy, a strong oncology clinical-trial ecosystem, presence of major developers such as Bristol Myers Squibb and Regeneron, and continued investment in next-generation immune-checkpoint combinations.

Competitive LAG-3 development also remains strong in the U.S. In May 2026, Regeneron reported that its Phase III study of fianlimab, a LAG-3 inhibitor, plus cemiplimab produced a 5.1-month numerical improvement in median progression-free survival versus pembrolizumab in first-line advanced melanoma, while a separate Phase III head-to-head trial against Opdualag remains ongoing.

Asia Pacific Lymphocyte Activation Gene-3 Protein Market Trends

Asia Pacific is expected to be the fastest-growing region in the Lymphocyte Activation Gene-3 Protein Market over the forecast period. The region’s growth is supported by expanding oncology drug-development capabilities, rising participation of Australian, Chinese, Indian, and Japanese biopharmaceutical companies, increasing clinical-trial activity, and growing licensing and commercialization interest in LAG-3-based therapies.

A major recent development occurred in December 2025, when Australia-based Immutep entered a strategic licensing and commercialization agreement with Dr. Reddy’s Laboratories for the LAG-3 protein eftilagimod alfa (efti) across territories including India and several emerging markets. Immutep received an upfront payment of USD 20 million and is eligible for up to USD 349.5 million in regulatory, development, and commercial milestone payments, in addition to double-digit royalties.

In June 2026, Sydney-based Immutep reported positive first-in-human Phase I results for IMP761, its first-in-class LAG-3 agonist antibody. The study met its primary safety endpoint and demonstrated statistically significant pharmacodynamic activity at the 7 mg/kg dose, supporting continued development of LAG-3 technology beyond oncology into autoimmune diseases.

Strong Late-stage Immuno-oncology Pipeline is Supporting the Lymphocyte Activation Gene-3 Protein Market in the United States

The U.S. Lymphocyte Activation Gene-3 Protein Market is expected to maintain a leading position owing to the early adoption of LAG-3-based immunotherapies, strong clinical-development infrastructure, and continued investment by companies such as Bristol Myers Squibb and Regeneron in next-generation LAG-3 combinations.

In August 2026, the FDA granted accelerated approval to vusolimogene oderparepvec-wtpg plus nivolumab for advanced melanoma following progression on PD-1-based therapy. In the supporting study, 24% of 91 patients achieved an objective response, with a median response duration of 14.1 months.

China Lymphocyte Activation Gene-3 Protein Market Trends

China is expected to witness strong growth in the Lymphocyte Activation Gene-3 Protein Market over the forecast period, supported by a rapidly developing domestic immuno-oncology pipeline, increasing development of novel checkpoint inhibitors, and regulatory initiatives designed to accelerate innovative biological drug trials.

Recent Chinese clinical evidence highlights this growing LAG-3 pipeline. A 2026 peer-reviewed study evaluating the Chinese LAG-3-blocking antibody DNV3 combined with toripalimab and chemotherapy in advanced melanoma reported an overall response rate of 44.4%. Among patients resistant to previous anti-PD-(L)1 treatment, the objective response rate was 42.9% with median progression-free survival of 7.36 months, while treatment-naïve mucosal melanoma patients achieved a 50% response rate.

Who are the Major Companies in Lymphocyte Activation Gene-3 Protein Industry

Some of the major key players in Lymphocyte Activation Gene-3 Protein Market are Bristol-Myers Squibb, Icell Kealex Therapeutics, Incyte Corporation, MacroGenics, Inc., GlaxoSmithKline Plc, Crescendo Biologics Ltd, Regeneron Pharmaceuticals Inc., Sutro Biopharma Inc., Symphogen A/S, Immutep Ltd.

Key News

• In September 2026, Immutep announced a focused development strategy for eftilagimod alfa (efti), its soluble LAG-3 protein, following its review of the TACTI-004 program. This followed several important 2026 milestones, including a fourth U.S. patent for efti combined with a PD-1 pathway inhibitor in July 2026 and Phase I results for IMP761, its first-in-class LAG-3 agonist antibody, which demonstrated significant pharmacodynamic activity at 7 mg/kg.

Market Report Scope

Lymphocyte Activation Gene-3 Protein Market Report Coverage

Analyst Opinion

• The Lymphocyte Activation Gene-3 Protein Market is transitioning from a single-product commercial story toward a broader immuno-oncology platform opportunity, driven by continued development of LAG-3 combinations across multiple tumor types. Bristol Myers Squibb’s RELATIVITY-1093 Phase III trial is evaluating relatlimab plus nivolumab and chemotherapy against pembrolizumab plus chemotherapy in first-line non-squamous NSCLC with PD-L1 expression of at least 1%, demonstrating the industry’s effort to expand LAG-3 use beyond melanoma.
• Competitive intensity is increasing as additional LAG-3 antibodies progress through late-stage development. In May 2026, Regeneron reported that fianlimab plus cemiplimab produced a 5.1-month numerical improvement in median progression-free survival, reaching 11.5 months versus 6.4 months with pembrolizumab in first-line advanced melanoma, although the primary endpoint did not achieve statistical significance. A separate Phase III head-to-head study against Opdualag remains ongoing, indicating that future market share will increasingly depend on differentiated efficacy, safety, dosing, and indication expansion.
• The market is also broadening beyond conventional LAG-3-blocking antibodies toward soluble LAG-3 proteins and agonist approaches. In July 2026, Immutep reported that biological responders across five eftilagimod alfa studies experienced a 7.7-month median overall-survival advantage, while its first-in-class LAG-3 agonist IMP761 met its primary safety endpoint and demonstrated significant pharmacodynamic activity in Phase I.

Market Segmentation

• By Drug (Revenue, USD Bn, 2021-2033)
  • BMS-986016 (Relatlimab)
  • IMP321 (Eftilagimod alfa)
  • IMP701 (Ieramilimab)
  • MGD013 (Tebotelimab)
  • Others
• By Cancer Type (Revenue, USD Bn, 2021-2033)
  • Breast Cancer
  • Melanoma
  • Solid Tumors
  • Others
• By Region (Revenue, USD Bn, 2021-2033)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • Central Africa
    • North Africa

Sources

Primary Research Interviews

• Medical oncologists and immuno-oncology specialists
• Clinical investigators involved in LAG-3 and immune checkpoint inhibitor trials
• R&D heads from oncology-focused biopharmaceutical companies
• Immunologists and cancer biology researchers
• Regulatory affairs and clinical development professionals
• Hospital oncology department heads and cancer center specialists
• Key opinion leaders (KOLs) in melanoma, lung cancer, and solid tumor immunotherapy

Databases

• U.S. Food and Drug Administration (FDA)
• ClinicalTrials.gov
• National Cancer Institute (NCI)
• National Institutes of Health (NIH)
• European Medicines Agency (EMA)
• World Health Organization (WHO)
• National Medical Products Administration (NMPA), China
• Health Canada Clinical Trials Database

Magazines

• Fierce Biotech
• BioPharma Dive
• Pharmaceutical Technology
• GEN – Genetic Engineering & Biotechnology News
• BioWorld
• The Cancer Letter

Journals

• Journal of Clinical Oncology
• The Lancet Oncology
• Nature Cancer
• Cancer Discovery
• Clinical Cancer Research
• Journal for ImmunoTherapy of Cancer
• Cancer Immunology Research
• New England Journal of Medicine

Newspapers / Business Publications

• Reuters
• Financial Times
• The Wall Street Journal
• Bloomberg
• The New York Times
• STAT News

Associations

• American Society of Clinical Oncology (ASCO)
• Society for Immunotherapy of Cancer (SITC)
• American Association for Cancer Research (AACR)
• European Society for Medical Oncology (ESMO)
• International Association for the Study of Lung Cancer (IASLC)
• Melanoma Research Alliance (MRA)

Public Domain Sources

• Company Annual Reports, SEC Filings, and Investor Presentations
• Company Clinical Pipeline and R&D Updates
• FDA Drug Labels, Approval Letters, and Regulatory Briefing Documents
• ClinicalTrials.gov Trial Registrations and Study Results
• Peer-reviewed Clinical Trial Publications and Conference Abstracts
• ASCO, ESMO, AACR, and SITC Conference Proceedings
• Patent Databases such as WIPO, USPTO, and Google Patents
• Government Oncology Statistics and Cancer Registry Publications
• Company Press Releases covering LAG-3 Pipeline, Regulatory, Licensing, and Clinical Developments

Proprietary Elements

• CMI Data Analytics Tool
• Proprietary CMI Existing Repository of Information for the Last 10 Years